Fractyl Health, Inc. (GUTS) Key Metrics
GUTS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $20.6M
- Enterprise value
- $90.3M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 5.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.42
GUTS key metrics, FY2019–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsGUTS valuation Price multiples at each fiscal year-end price.
GUTS returns How much profit the business earns on the capital it uses.
GUTS per-share figures Results divided by the shares outstanding at year-end.
GUTS financial health Debt, liquidity and how easily interest is covered.
GUTS efficiency & capital use Working capital cycle and where the cash goes.
GUTS valuation history
GUTS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GUTS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GUTS price vs earnings per share
GUTS key metrics
FY2019–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $243.9M | $110.2M | — | — | — | — | — |
| Enterprise value | $224.0M | $105.2M | — | — | — | — | — |
| Price / book | 25.8 | 3.9 | — | — | — | — | — |
| Earnings yield | −57.8% | −62.4% | — | — | — | — | — |
| Free cash flow yield | −37.3% | −61.1% | — | — | — | — | — |
| Share price at fiscal year-end | $19.08 | $30.36 | — | — | — | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.03 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$11.03 | −$18.93 | −$1.62 | −$11.71 | −$0.81 | −$0.64 | −$0.64 |
| Operating cash flow per share | −$7.07 | −$18.06 | −$0.90 | −$11.66 | −$0.70 | −$0.65 | −$0.58 |
| Free cash flow per share | −$7.11 | −$18.54 | −$0.91 | −$11.67 | −$0.70 | −$0.65 | −$0.58 |
| Cash per share | $6.38 | $18.59 | $0.70 | $12.42 | $2.01 | $0.61 | $0.12 |
| Book value per share | $0.74 | $7.83 | −$6.83 | −$63.60 | −$4.40 | $0.31 | −$3.02 |
| Tangible book value per share | $0.74 | $7.60 | −$6.85 | −$63.82 | −$4.40 | $0.31 | −$3.02 |
| Capex per share | $0.04 | $0.49 | $0.01 | $0.01 | $0.00 | $0.00 | $0.00 |
| Debt per share | $4.82 | $17.22 | $1.81 | $77.33 | $6.39 | $0.32 | $0.31 |
| Shares outstanding | 12.8M | 3.6M | 47.6M | 4.0M | 47.6M | 47.6M | 47.6M |
| Change in shares outstanding | +252.2% | −92.4% | +1,100.0% | −91.7% | 0.0% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −744.2% | — | — | — | — | — | — |
| Return on assets (ROA) | −122.8% | −74.6% | −112.4% | −56.8% | −56.4% | −139.5% | −342.4% |
| Return on tangible assets | −116.1% | −64.1% | −102.3% | −77.3% | −37.8% | −87.7% | −342.4% |
| Financial health | |||||||
| Total debt | $61.6M | $62.5M | $86.4M | $306.8M | $304.3M | $15.3M | $14.9M |
| Cash & short-term investments | $81.5M | $67.5M | $33.2M | $49.3M | $95.5M | $29.1M | $5.8M |
| Net debt | −$19.9M | −$5.0M | $53.2M | $257.5M | $208.9M | −$13.8M | $9.1M |
| Debt / equity | 6.52 | 2.20 | — | — | — | 1.02 | — |
| Debt / assets | 0.51 | 0.58 | 1.13 | 5.03 | 2.97 | 0.44 | 1.67 |
| Current ratio | 4.78 | 3.63 | 3.19 | 7.06 | 4.07 | 2.83 | 1.99 |
| Quick ratio | 4.78 | 3.63 | 3.18 | 7.06 | 4.07 | 2.83 | 1.99 |
| Interest coverage | — | — | — | — | -25.6 | -19.3 | -47.1 |
| Working capital | $69.2M | $52.0M | $24.5M | $44.3M | $72.7M | $20.0M | $3.4M |
| Invested capital | −$10.4M | $23.5M | −$271.9M | $5.2M | −$460,000 | $1.1M | −$134.9M |
| Tangible asset value | $9.5M | $27.6M | −$325.9M | −$253.2M | −$209.3M | $15.0M | −$144.0M |
| Net current asset value | −$24.4M | −$7.9M | −$365.6M | −$261.6M | −$215.5M | $11.1M | −$146.2M |
| Graham net-net per share | −$2.38 | −$3.34 | −$7.73 | −$66.55 | −$4.55 | $0.20 | −$3.09 |
| Capital allocation | |||||||
| Capex / revenue | — | 1,897.8% | 299.2% | — | — | — | — |
| Capex / depreciation | 0.49 | 2.61 | 1.26 | 0.12 | 0.08 | 0.00 | 0.11 |
| Stock-based compensation / revenue | — | 15,511.8% | 3,580.0% | — | — | — | — |
| R&D / revenue | — | 75,775.3% | 31,698.3% | — | — | — | — |
| SG&A / revenue | — | 24,841.9% | 10,700.8% | — | — | — | — |
| Efficiency | |||||||
| Days sales outstanding | — | 86.3 | 33.5 | — | — | — | — |
| Days of inventory on hand | — | 532.9 | 173.0 | — | — | — | — |
| Days payables outstanding | 778.2 | 13,844.5 | 3,633.4 | 787.3 | 343.9 | 216.2 | 248.5 |
| Cash conversion cycle (days) | — | -13,225.2 | -3,426.9 | — | — | — | — |
| Receivables turnover | — | 4.23 | 10.91 | — | — | — | — |
| Payables turnover | 0.47 | 0.03 | 0.10 | 0.46 | 1.06 | 1.69 | 1.47 |
| Inventory turnover | — | 0.68 | 2.11 | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | $22,000 | $11,000 | $0 | — | — | — |
| Average payables | $2.4M | $1.9M | $766,500 | $975,000 | $637,000 | $456,000 | $608,000 |
| Average inventory | $36,500 | $73,000 | $36,500 | $0 | — | — | — |
| Intangibles / total assets | 0.0% | 0.8% | 1.1% | 1.4% | 0.0% | 0.0% | 0.0% |
Computed from GUTS's annual financial statements (latest annual report filed March 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GUTS valuation and financial ratios
Fractyl Health earned a return on equity of −744.2% in fiscal 2025. It ended the year with $61.6 million of debt and $81.5 million in cash and short-term investments, a net cash position of $19.9 million. The share count fell 73.2% from 47.6M to 12.8M over 6 years.
See the GUTS income statement, the GUTS chart for price history, or the GUTS stock overview for the latest quote and news.
GUTS key metrics FAQ
What is Fractyl Health's return on equity?
Fractyl Health's return on equity (ROE) was −744.2% in fiscal 2025: net income of -$141.0 million on average shareholders' equity of $18.9 million.
How much debt does Fractyl Health have?
Fractyl Health had total debt of $61.6 million at the end of fiscal 2025, a debt-to-equity ratio of 6.52 and more cash than debt.
What is Fractyl Health's free cash flow yield?
Fractyl Health generated -$90.9 million of free cash flow in fiscal 2025, a free cash flow yield of −37.3% on its market value at year-end ($243.9 million).
What is Fractyl Health's current ratio?
Fractyl Health's current ratio was 4.78 at the end of fiscal 2025: current assets were 4.78 times current liabilities.